NCT04454424View on ClinicalTrials.gov

Study on the Safety of BAY1817080, How it is Tolerated and the Way the Body Absorbs, Distributes and Gets Rid of the Study Drug in Participants With Impaired Liver Function or Normal Liver Function

PHASE1CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

July 23, 2020

Primary Completion Date

June 24, 2021

Study Completion Date

December 15, 2021

Conditions
Endometriosis Related PainOveractive BladderDiabetic Neuropathic PainRefractory or Unexplained Chronic Cough
Interventions
DRUG

BAY1817080

Study intervention BAY1817080 will be administered orally with tablet(s).

DRUG

Midazolam

Midazolam will be administered intravenously with dose of 0.1 mg on Day 1.

Trial Locations (2)

32806

Orlando Clinical Research Center, Orlando

33014

Clinical Pharmacology of Miami, LLC, Miami

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY